HANNAH ALISON L.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CTMX to Present at September Investor Conferences. CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.
Transaction History
| RIGL | ▲ Buy | Grant | 24,400 | $0 | 7/8/2026 | View on chart |
| RIGL | ▲ Buy | Grant | 5,750 | $0 | 5/15/2026 | View on chart |
| NEO | ▲ Buy | Grant | 12,254 | $0 | 6/1/2025 | View on chart |
| RIGL | ▲ Buy | Grant | 2,500 | $0 | 5/23/2025 | View on chart |
| NEO | ▲ Buy | Option Exercise | 11,336 | $0 | 8/10/2024 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/25/2024 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/26/2023 | View on chart |
| CTMX | ▼ Sell | Open Market | 5,602 | $8K | 7/20/2022 | View on chart |
| CTMX | ▲ Buy | Grant | 15,000 | $0 | 7/19/2022 | View on chart |
| NEO | ▲ Buy | Grant | 15,556 | $0 | 6/10/2022 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/20/2022 | View on chart |
| CTMX | ▲ Buy | Grant | 22,500 | $0 | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified
Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.